<?xml version="1.0" encoding="UTF-8"?>
<p>Given the heterogeneity of the disorder and its economic and social burden, PTSD represents a challenge for safe and effective treatment [
 <xref rid="B20-life-11-00214" ref-type="bibr">20</xref>]. Despite more psychological treatment approaches for PTSD [
 <xref rid="B21-life-11-00214" ref-type="bibr">21</xref>,
 <xref rid="B22-life-11-00214" ref-type="bibr">22</xref>], the Food and Drug Administration (FDA) approved only two pharmacological treatments for PTSD, the Selective Serotonin Reuptake Inhibitors (SSRIs) paroxetine and sertraline [
 <xref rid="B23-life-11-00214" ref-type="bibr">23</xref>] that do not display certain effectiveness in producing a clinical remission and may be responsible for several side effects [
 <xref rid="B24-life-11-00214" ref-type="bibr">24</xref>,
 <xref rid="B25-life-11-00214" ref-type="bibr">25</xref>], which can sometimes reduce treatment compliance [
 <xref rid="B26-life-11-00214" ref-type="bibr">26</xref>]. 
</p>
